WilmerHale provides legal representation across a comprehensive range of practice areas critical to the success of its clients. With a staunch commitment to public service, the firm is a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia.
On January 18, 2018, Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, announced its $58 million Series A financing.
United States
On January 18, 2018, Pandion Therapeutics, Inc., a biotechnology
company developing bispecific antibody therapeutics to achieve
localized immunomodulation, announced its $58 million Series A
financing. Pandion intends to use the proceeds to advance
tissue-specific immune modulator drugs for autoimmune and
inflammatory diseases. The round was led by Polaris Partners,
Versant Ventures, and Roche Venture Fund, with participation from
SR One and BioInnovation Capital.
WilmerHale provides legal representation across a comprehensive range of practice areas critical to the success of its clients. With a staunch commitment to public service, the firm is a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia.
